SparingVision SparingVision

SparingVision to Participate in Upcoming Scientific and Medical Conferences

SparingVision to Participate in Upcoming Scientific and Medical Conferences

Paris, October 25, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces the upcoming scientific and medical conferences that its management team will be participating in:

 

ASHG (American Society of Human Genetics) Annual Meeting 2022- 25-29 October

  • Poster presentation: Genotyping Analysis in patients with retinitis pigmentosa due to mutations in the RHO, PDE6A, or PDE6B gene: the PHENOROD2 study

Daniel Chung, DO, MA, Chief Medical Officer, (October 26, 3:00pm- 4:45pm PDT)

 

Korean American Society of Biotech and Pharmaceuticals 2022 Fall Symposium – 4-5 November

  • Moderator, Cell and Gene Therapy networking event (November 4, 9:30pm EST)
  • Panel, KASDP-KHIDI Cell and Gene Therapy Saturday (November 5, 8:20-9:35am EST)
    Daniel Chung, DO, MA, Chief Medical Officer

 

Innovation in Ophthalmology, 3rd French-Japanese Conference – 9 November

  • Presentation, Retinal gene therapy, the breakthrough, the challenges and the future, featuring gene independent approaches

Daniel Chung, DO, MA, Chief Medical Officer (5:10-5:40pm JST)

  

American College of Toxicology Annual Meeting- 13-16 November

  • Poster presentation: Nonclinical Safety Assessment of SPVN06, an AAV-based Gene Therapy for the Treatment of Rod-Cone Dystrophies

Mélanie Marie, Ph. D. (November 14, 5:00-6:30 pm MST)

  • Poster presentation: SPVN06, a Novel Gene-Independent AAV-Based Gene Therapy, Dramatically Slows Down Vision Loss and Protects Cone Morphology in the rd10 Mouse Model of Rod-Cone Dystrophy,

Lucie Churet (November 14, 5:00-6:30 pm MST).

 

Gene Therapy Area of Major Interest network (DIM Thérapie Génique) 2022 Symposium “Gene Therapy Revolution Underway: the latest advances” – 16 November

  • Presentation, Deniz Dalkara, Ph.D. Chief Scientific Officer (CSO) (November 16, 4pm CET)

 

NSGC (National Society of Genetic Counselors) 41st Annual Conference, 16-20 November

  • Presentation: Ocular Gene Therapy: Challenges, Breakthroughs, and Genetic Counsellors, Educational Breakout session (EBS)

Daniel Chung, DO, MA, Chief Medical Officer (November 18, 10:30am-12pm EST)

 

Ophthalmic Drugs 2022 Conference – 21-22 November

  • Presentation: Gene Independent approaches to Gene Therapy for Inherited Retinal Diseases, (November 21, 4:30 pm GMT)
  • Panel Discussion: Challenges and opportunities with using genetic therapy for inherited retinal diseases (November 21, 5:10 pm GMT)

Daniel Chung, DO, MA, Chief Medical Officer

 

European Reference Network-EYE Workshop, Ghent, Belgium, 1-2 December

  • Panel, Daniel Chung, DO, MA, Chief Medical Officer

**ENDS**

 

© SparingVision